Cynata raises $1.5 million ahead of Phase 3 osteoarthritis and Phase 2 aGvHD readouts
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
Cynata Therapeutics has secured firm commitments to raise $1.5 million through an institutional placement ahead of key clinical trial results expected in May and June 2026. The placement is intended to strengthen the company’s cash runway and support potential commercial partnerships and working capital as it awaits a Phase 3 osteoarthritis readout and a Phase 2 acute graft-versus-host disease (aGvHD) readout.
The company priced the placement at $0.25 per share, representing a 22.5% discount to its last traded price of $0.323 on April 29, 2026. The company expects settlement of the placement on May 7, 2026, with allotment of shares on May 8, 2026.
Cynata said proceeds will be used to pursue potential commercial partnerships following results from its Phase 3 osteoarthritis trial expected in May 2026 and Phase 2 acute graft-versus-host disease trial expected in June 2026. The company said both advanced clinical trials are fully recruited and readouts are expected in Q2 CY26.
Cynata’s Phase 2 trial of CYP-001 in adults with acute graft versus host disease has completed the 100-day primary evaluation period for all 65 participants, marking the last-patient, last-visit milestone in the randomized, double-blind, placebo-controlled study. Data are being compiled and analyzed ahead of a results readout expected in June 2026.
Acute graft-versus-host disease is a serious and often life-threatening complication of bone marrow transplantation and similar procedures, where the donor’s immune cells attack the recipient’s tissues. aGvHD affects up to 50% of patients who receive transplants from other donors, and standard treatments involving steroids typically fail in about half of all cases, with two-year survival rates in such patients sitting at less than 20%.
Cynata said CYP-001 is designed to modulate the immune system. In a Phase 1 trial, CYP-001 achieved an 87% overall response rate, a 53% complete response rate, and a two-year survival rate of 60%. The US FDA has granted Orphan Drug Designation to CYP-001 for the treatment of aGvHD.
The company’s Phase 3 osteoarthritis trial involves a two-year follow-up of participants in the Phase 3 SCUlpTOR trial of CYP-004 in patients with osteoarthritis of the knee. CYP-004 was given to a total of 321 patients, who were randomised to receive either CYP-004 or placebo, with co-primary endpoints of changes in pain and cartilage thickness.
Cynata said positive results could support market approval of CYP-004 in Australia, following an advisory meeting with the TGA. The company said its Cymerus platform uses induced pluripotent stem cells to create a renewable mesenchymal stem cell supply from a single donation, producing highly consistent batches at near-unlimited scale.